Prostate Cancer | Specialty

Impact of Abiraterone Evident in New AUA Guidelines for mCRPC

August 15th 2013

Amid a flurry of new drug approvals, the AUA has issued its first set of guidelines for the management of patients with mCRPC, which included an extensive role for abiraterone acetate at several stages of the disease.

Isoform Test Tops PSA, fPSA for Cancer Detection

August 2nd 2013

An assay based on a prostate-specific antigen isoform performed significantly better than did conventional PSA measures for detecting prostate cancer and identifying histopathologically aggressive cancers.

Some Prostate Cancers Unaffected, Others Prevented With 5ARIs

July 29th 2013

Investigators say they have found no association between the use of 5-alpha-reductase inhibitors (5ARIs) and the risk of developing high-grade or lethal prostate cancer.

Prostate Cancer Gene Test Could Boost Active Surveillance

July 25th 2013

An assay based on tumor genetics showed potential for stratifying risk in prostate cancer patients and aiding selection of men for active surveillance.

Dr. Shore on Degarelix Versus LHRH Agonists

July 24th 2013

Neal D. Shore, MD, FACS, discusses an analysis of degarelix and luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer.

Dr. George on Radium-223 in Combinations for mCRPC

July 17th 2013

Daniel J. George, MD, from the Duke Cancer Institute, discusses the potential to incorporate radium-223 into combination strategies to treat patients with metastatic castation-resistant prostate cancer.

Genetic Alterations Linked to Poorer Prostate Cancer Prognosis

July 16th 2013

Alterations in the chromosomes of two genes have been implicated in an increased risk of prostate cancer mortality, and the discovery holds promise for distinguishing which patients are candidates for more aggressive therapy.

Dr. Sartor on the Mechanism of Action of Radium-223

July 12th 2013

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, describes the mechanism of action of radium-223 for bone metastases from prostate cancer.

Conclusion: Final Thoughts on Treating mCRPC

July 10th 2013

Case Study: Managing Symptomatic mCRPC

July 10th 2013

Case Study: Minimally Symptomatic mCRPC

July 10th 2013

Treatment With Sipuleucel-T in Advanced Prostate Cancer

July 10th 2013

Utilizing Early Imaging to Detect Metastatic CRPC

July 10th 2013

Dr. Finkelstein Summarizes the Development of Radium-223

July 10th 2013

Dr. Finkelstein Discusses Radium-223 Reimbursement

July 10th 2013

Dr. Finkelstein Discusses the Safety Profile of Radium-223

July 10th 2013

Dr. Finkelstein Describes the Phase III ALSYMPCA Trial

July 10th 2013

Dr. George on Radium-223 for Patients With mCRPC, Part II

July 10th 2013

Dr. George on Radium-223 for Patients With mCRPC, Part I

July 10th 2013

Case Study: Treating Asymptomatic mCRPC

July 10th 2013